CORESTEM Inc Cash Flow Conversion Efficiency

Latest as of September 2025: -0.103x

CORESTEM Inc cash flow conversion efficiency. Based on the latest financial reports, CORESTEM Inc (166480) has a cash flow conversion efficiency ratio of -0.103x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-4.18 Billion ≈ $-2.83 Million USD) by net assets (₩40.62 Billion ≈ $27.53 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of CORESTEM Inc (2014–2024)

Cash flow conversion efficiency of CORESTEM Inc from 2014 to 2024. This chart illustrates how CORESTEM Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 166480 share price today for real-time trading data and today's change.

CORESTEM Inc Cash Flow Conversion Ratio Explained

CORESTEM Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

CORESTEM Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of CORESTEM Inc ranked by their cash flow conversion efficiency. Also see CORESTEM Inc market cap and net worth for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
Lulu's Fashion Lounge Holdings Inc
NASDAQ:LVLU
-13.143x
Kyung Chang Industrial Co. Ltd
KQ:024910
0.105x
Uniti SA
PA:ALUNT
-0.156x
CID HoldCo, Inc. Common Stock
NASDAQ:DAIC
0.323x
Pion Group AB Series B
ST:PION-B
-0.103x
HICL Infrastructure Company Ltd
LSE:HICL
0.026x
Gome Telecom Equipment Co Ltd
SHG:600898
-0.051x
PTRB
KLSE:0260
0.084x

Annual Cash Flow Conversion Efficiency for CORESTEM Inc (2014–2024)

The table below shows the annual cash flow conversion efficiency of CORESTEM Inc from 2014 to 2024. Review 166480 cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 ₩48.59 Billion
≈ $32.93 Million
₩-21.12 Billion
≈ $-14.31 Million
-0.435x +45.73%
2023-12-31 ₩19.60 Billion
≈ $13.28 Million
₩-15.70 Billion
≈ $-10.64 Million
-0.801x -294.34%
2022-12-31 ₩41.46 Billion
≈ $28.10 Million
₩-8.42 Billion
≈ $-5.71 Million
-0.203x +1.23%
2021-12-31 ₩37.19 Billion
≈ $25.20 Million
₩-7.65 Billion
≈ $-5.18 Million
-0.206x -290.05%
2020-12-31 ₩41.29 Billion
≈ $27.98 Million
₩4.47 Billion
≈ $3.03 Million
0.108x +1260.00%
2019-12-31 ₩57.70 Billion
≈ $39.10 Million
₩-538.08 Million
≈ $-364.65K
-0.009x +48.55%
2018-12-31 ₩62.24 Billion
≈ $42.18 Million
₩-1.13 Billion
≈ $-764.48K
-0.018x +81.10%
2017-12-31 ₩65.60 Billion
≈ $44.46 Million
₩-6.29 Billion
≈ $-4.26 Million
-0.096x -282.69%
2016-12-31 ₩66.73 Billion
≈ $45.22 Million
₩3.50 Billion
≈ $2.37 Million
0.053x +424.60%
2015-12-31 ₩63.04 Billion
≈ $42.72 Million
₩-1.02 Billion
≈ $-691.01K
-0.016x +87.47%
2014-12-31 ₩18.97 Billion
≈ $12.86 Million
₩-2.45 Billion
≈ $-1.66 Million
-0.129x --

About CORESTEM Inc

KQ:166480 Korea Biotechnology
Market Cap
$30.92 Million
₩45.63 Billion KRW
Market Cap Rank
#23470 Global
#1613 in Korea
Share Price
₩1624.00
Change (1 day)
+1.69%
52-Week Range
₩1060.00 - ₩4800.00
All Time High
₩32150.00
About

CORESTEMCHEMON Inc., a bio-pharmaceutical company, engages in the development and production of stem cell therapies for the treatment of incurable diseases in South Korea. It offers NEURONATA-R inj, an autologous bone marrow mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company also engages in the development of various therapy products for the treatm… Read more